ARVINAS PRESENTS A PLATFORM UPDATE, INCLUDING INITIAL DATA FROM THE FIRST TWO CLINICAL TRIALS OF PROTAC® TARGETED PROTEIN DEGRADERS -Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally...
HARPOON THERAPEUTICS AND ABBVIE ANNOUNCE LICENSING AND OPTION COLLABORATION TO ADVANCE HPN217, HARPOON’S BCMA-TARGETING TRITAC®, AND EXPAND EXISTING DISCOVERY COLLABORATION Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the...
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection Topline results expected in Q1 2020 DUBLIN, Ireland and CHICAGO, Nov. 18, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics...
New Patient Access Survey Shows Consumers Are Increasingly Self-Empowered in Their Care Decisions and Place a Growing Premium on Convenience Third Annual Survey from Kyruus Underscores the Need for Health Systems to Meet Patient Demand for Streamlined Access and...
Neurana Pharmaceuticals Appoints Randall Kaye, M.D., Chief Medical Officer SAN DIEGO, Calif., November 7, 2019 – Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that it has appointed...
Recent Comments